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An extensive literature describes the positive impact of dietary phytochemicals on overall health and longevity.
Dietary phytochemicals include a large group of non-nutrients compounds from a wide range of plant-derived
foods and chemical classes. Over the last decade, remarkable progress has been made to realize that oxidative and
nitrosative stress (O&NS) and chronic, low-grade inflammation are major risk factors underlying brain aging.
Accumulated data strongly suggest that phytochemicals from fruits, vegetables, herbs, and spices may exert
relevant negative immunoregulatory, and/or anti-O&NS activities in the context of brain aging. Despite the
translational gap between basic and clinical research, the current understanding of the molecular interactions
between phytochemicals and immune-inflammatory and O&NS (IO&NS) pathways could help in designing effective
nutritional strategies to delay brain aging and improve cognitive function. This review attempts to summarise
recent evidence indicating that specific phytochemicals may act as positive modulators of IO&NS pathways by
attenuating pro-inflammatory pathways associated with the age-related redox imbalance that occurs in brain aging.
We will also discuss the need to initiate long-term nutrition intervention studies in healthy subjects. Hence, we will
highlight crucial aspects that require further study to determine effective physiological concentrations and explore
the real impact of dietary phytochemicals in preserving brain health before the onset of symptoms leading to
cognitive decline and inflammatory neurodegeneration.
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Over the next few decades, given the rising life expectancy
within the older population, the incidence of developing
age-related neurodegenerative diseases is predicted to in-
crease dramatically. A critical factor that plays a crucial
role in brain aging is the exceptionally high energy de-
mand of neurons to preserve neuronal processes and
maintain cognitive ability. The high consumption of oxy-
gen for the generation of energy may reflect more vul-
nerability of the brain to reactive species attack and
subsequent inflammation [1]. In addition, normal brain
metabolism is associated with more than one process* Correspondence: s.davinelli@gmail.com
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instance, high content of polyunsaturated fatty acids
(PUFAs) in neuronal membranes (easily peroxidizable),
limited amount of endogenous antioxidant defences, low
rate of cell turnover, and high production of reactive oxy-
gen and nitrogen species (ROS/RNS) put the brain at risk
to oxidative and nitrosative (O&NS) damage [2]. It should
be also mentioned that the age-related redox imbalance
underlying the pathophysiological basis of neurodegenera-
tion is accompanied by many types of cellular damages,
including oxidative DNA and lipid damage, oxidative and
nitrosative protein damage, mitochondrial damage, telo-
mere attrition and accumulation of macromolecular waste
[2, 3]. Growing studies suggest that a bidirectional com-
munication between brain and immune system is crucial
to maintain central nervous system (CNS) homeostasis.
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uncontrolled production of reactive species and pro-
inflammatory cytokines [4, 5]. This chronic condition has
been defined as “oxi-inflammaging” and may contribute to
neuronal loss in different neurodegenerative diseases, cul-
minating in accelerated neurodegeneration [6–9]. During
brain aging, the generation of ROS and RNS increases the
synthesis of numerous chemokines and pro-inflammatory
cytokines, including interleukin (IL)-1, IL-6, and tumor
necrosis factor- α (TNF-α). These inflammatory mediators
activate microglia and astrocytes to generate large amounts
of ROS/RNS. Recent studies showed that neuroinflamma-
tory processes may be considered as a consequence of
chronic oxidative stress [10, 11]. Moreover, the neuro-
pathological alterations associated with oxidative stress
and pro-inflammatory state include deposition of insol-
uble materials such as amyloid-β (Aβ) plaques and neuro-
fibrillary tangles (NFTs), which are the main factors of cell
death and age-related dementia [12].
However, it is now becoming clear that the consump-
tion of diets rich in phytochemicals can influence neuro-
inflammation and mediate the activation of signaling
pathways, leading to the expression of cytoprotective
and restorative proteins [13, 14]. There is substantial
evidence supporting the notion that bioactive dietary
components may contribute to develop novel therapies
capable of preventing the progressive dysfunction of
neuronal populations that underlie neurodegeneration
[15, 16]. A large variety of foods including fruit, vegeta-
bles, cereals, nuts and cocoa/chocolate as well as tea,
coffee and wine contain a wide range of plant secondary
metabolites, better known as phytochemicals, which
have been shown to be effective in increasing antioxi-
dant enzymes, neurotrophic factors and anti-apoptotic
proteins. Several mechanisms have been proposed for
the health benefits of phytochemicals, however, their
ability to modulate signal transduction cascades and ac-
tivate transcription factors that antagonize neuroinflam-
mation and O&NS has attracted considerable interest
[17]. Despite various beneficial biological activities, phy-
tochemicals may have carcinogenic or genotoxic effects
at high doses or concentrations [18]. Therefore, the chal-
lenge is to establish the exact dose range and perform
human intervention studies to develop effective nutri-
tional strategies capable of counteracting neuroinflam-
matory processes that accompany brain aging. Here, we
discuss some of the new findings that provide insight
into how phytochemicals positively affect neuroinflam-
mation and brain aging. Specifically, we will discuss the
main neuroprotective activities of phytochemicals that
have been studied in cells, animals and humans empha-
sizing the importance of dosage, which is crucial to es-
tablish endpoints for clinical studies and develop dietary
recommendations.Oxidative stress, microglial redox activation and
neuroinflammation
Aging is associated with an imbalance in redox status in
a variety of cells and tissues, including the brain. In-
creasing O&NS stress is thought to be one of the main
aging processes causing direct cell loss and cell damage
within the brain architecture [19–21]. An age-associated
increase in O&NS damage has been shown in neurons
of human and rodent brains, and a selective susceptibil-
ity of different neuronal populations to oxidative stress
has been demonstrated. For instance, oligodendrocytes
are particularly vulnerable to oxidative activity due to
their role in myelin maintenance and production and
limited repair mechanisms [22]. Neuronal oxidation can
lead to the destruction of subcellular structures and
membranes. Indeed, during brain aging, in addition to
the impaired function of many intracellular components
such as mitochondrial electron transport chain, various
important classes of macromolecules are particularly li-
able to the deleterious effects of oxidative modification.
Several studies have indicated that oxidative damage to
nucleic acids can actively contributes to the background,
onset, and development of neurodegenerative disorders
[23]. Age-associated accumulation of oxidative DNA
damage such as the presence of the modified base 8-
hydroxydeoxyguanosine (8-OHdG), was observed in
many neuron types, including cerebellar granule cells,
retinal ganglion, and amacrine, and horizontal cells [24].
Interestingly, it has been recently demonstrated in hu-
man neurons that oxidative RNA modification can occur
not only in protein-coding RNAs but also in non-coding
RNAs, leading to activate inappropriate cell fate path-
ways [23]. Oxidative damage of the brain is also charac-
terized by increased lipid peroxidation and it has been
shown that redox changes in membrane fatty acid
composition contribute to the deterioration of neuronal
functions. PUFAs, such as arachidonic acid (AA), are
abundant in the brain and are highly susceptible to free
radical attack during brain aging [25].
Hypernitrosylation may inhibit the functions of many
different proteins involved in critical cell functions lead-
ing to apoptosis, dysfunctions in intracellular signalling,
inhibition of cell growth, mitochondrial functions, cell
death, etc. [20]. Another consequence of nitrosative stress
is the formation of immunogenic neoepitopes, e.g. nitroso
(NO)-tyrosine and NO-tryptophan which may mount
autoimmune responses, e.g. IgM-mediated autoimmune
responses to NO-cysteinyl [20]. The latter autoimmune
responses may have neurotoxic effects and cause demye-
lination. Hypernitrosylation is tightly coupled to nuclear
factor (NF)- κB activation which induces and supports
inflammaging and induction of inducible NO-synthase
(iNOS). An age-related NF-κB constitutive activation was
observed in many tissues including brain [26]. Increased
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nitro (NO2)-tyrosine, accompanies the aging process [27].
Besides oxidation of nucleic acids, lipids, and proteins,
and nitrosylation, nitrosation and nitration of proteins, an
excess of free radical generation is associated with chronic
low-grade inflammation and the onset of age-related brain
disorders [28]. The role of an excessive free radical pro-
duction linked to persistent low-basal inflammation and
brain aging is schematized in Fig. 1. In the CNS, reactive
species, glial cells and inflammatory mediators form a co-
ordinated network to maintain a proper equilibrium be-
tween physiological and pathological processes. In the
brain, glial cells (mainly microglia) provide the first line of
defense against noxious agents or injurious processes [29].
Microglial cells are the resident macrophages of the CNS
and under physiological conditions they exhibit a deac-
tivated phenotype. A tight control of microglial inflam-
matory response is essential for CNS homeostasis to
promote the clearance of pathogens, toxic cellular deb-
ris and stimulate repair processes after brain damage.
However, microglia are a potent cellular source of oxi-
dation products and inflammatory molecules during
brain aging. Microglia respond to oxidative damage, as
a result of aging or neurodegeneration, by releasing a
large spectrum of neuroactive mediators. The accumu-
lation of oxidative damage in microglia during aging
results in the increased production of ROS. Dispropor-
tional increase in intracellular ROS can activate theIMPAIRED REDOX
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Fig. 1 Oxidative stress, chronic inflammation and brain aging are closely linke
stress to inflammation and brain agingredox-sensitive NF-κB and provoke excessive neuroin-
flammation [30]. A sustained activation of microglia may
lead to neuronal degeneration and dysfunction, as ob-
served in brain aging, cognitive and neuropsychiatric dis-
orders [31]. An interruption in microglial homeostasis, a
process referred to as microglial priming, makes the
microglia more susceptible to inflammatory stimuli and
neurodegeneration and may be an early events leading to
oxidative damage and depletion of endogenous antioxi-
dants [32]. The causal relationship between oxidative dam-
age and neuroinflammatory response is exemplified by the
cytokine TNF-α, which is released by activated microglia.
Although TNF-α can ameliorate immune responses and
promote neuroprotection, under uncontrolled conditions
TNF-α is a powerful pro-inflammatory and neurotoxic
molecule. In particular, TNF-α can contribute to neuroin-
flammation by activating the transcription factor NF-κB in
glia cells, but also promoting the generation and release of
ROS through the NADPH oxidase system and RNS [4, 33,
34]. In addition, recent findings suggest that the dysregula-
tion of Toll-Tike receptors (TLRs) participate to generate
a hyperactivated state of microglia. A persistent activation
of TLRs, their signalling pathways and downstream ef-
fector molecules, may contribute to cytotoxic compounds
accumulation such as ROS, RNS, cytokines, complements
and proteases causing neuronal loss and damage [35, 36].
The formation of redox-derived damage-associated mo-
lecular patterns (DAMPs), may further activate the TLR4 HOMEOSTASIS 
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cycle, thereby causing chronic IO&NS [37]. Additional
pro-inflammatory markers, including interleukin (IL)-6, C-
reactive protein (CRP), matrix metalloproteinases (MMPs),
cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2
(COX-2) and TNF-α are consistently elevated in neuro-
degenerative diseases, which are largely associated with
chronically elevated levels of ROS [5, 38]. Moreover, it has
been hypothesized that IL-6 is a central regulator of the
neuroinflammatory responses in brain aging. Animal
models and patients with neurodegenerative diseases had
higher levels of IL-6 and CRP, providing evidence that
peripheral inflammatory mediators can increase ROS pro-
duction and also interfere with neurocognitive functions
[39–41]. There is growing interest in the redox patho-
physiology of neuroinflammation and emerging concepts
open new ways to restore the inactive state of microglia
and modulate the low-grade chronic neuroinflammation
that characterizes brain aging.
Neuroprotective signaling pathways
Dietary phytochemicals exert their beneficial effects on
the nervous system modulating cellular stress response
signaling pathways [42]. At low doses, several phytochem-
icals are known to enhance neuronal stress resistance,
whereas at high doses many different phytochemicals can
be toxic. This is an example of biphasic dose–response re-
lationship with stimulatory or beneficial effects at low
doses and inhibitory or adverse effects at high doses
(hormesis) [43]. Therefore, dietary phytochemicals act as
mild stressors to induce adaptive expression of stress-
protective genes in neuronal cells and enhance resistance
to the mechanisms that determine brain aging. In the next
sections, we highlight the major signaling pathways by
which dietary phytochemicals offer neuroprotection in an
exposure-related manner.
The Nrf2 antioxidant response pathway
The transcription factor nuclear factor E2-related factor 2
(Nrf2) has emerged as a key cytoprotective regulator
against O&NS stress and neuroinflammation [44]. Nrf2 is
a member of the cap‘n’collar (CNC) family of stress-
sensing transcription factors. Nrf2 is a basic leucine zipper
protein that in the nucleus heterodimerizes with small
Maf protein followed by binding to specific DNA sites
termed antioxidant response elements (AREs) or electro-
phile response elements (EpRE) [45]. In basal conditions,
Nrf2 is kept transcriptionally inactive and sequestered in
the cytoplasm by its repressor protein, the Kelch-like
ECH-associated protein 1 (Keap1). This binding provides
the turnover of Nrf2 through proteasomal degradation.
Keap1, a sulfhydryl-rich protein, is a specialized sensor to
quantify stress in presence of oxidative stressors and
electrophilic xenobiotics. In response to oxidative and/orelectrophilic stress, Nrf2-Keap1 dissociation is triggered
with consequent translocation of Nrf2 to the nucleus,
where the formed heterodimer with Maf binds ARE se-
quence in the promoter regions of genes involved in phase
II detoxification and antioxidant defense [46]. Nrf2 is ubi-
quitously present in all tissues but is widely expressed in
the CNS where it promotes cell survival and coordinates
the transcription of neuroprotective proteins. Some exam-
ples include various superoxide dismutase (SOD) iso-
forms, catalase (CAT), glutathione peroxidase, glutathione
reductase, various glutathione-S-transferase (GST) iso-
forms, NAD(P)H:quinone oxidoreductase 1 (NQO1), and
heme oxigenase-1 (HO-1). However, recent findings have
linked the activation of the Nrf2 signaling not only to
phase II detoxifying enzymes and antioxidants proteins
but also to expression of other cytoprotective proteins
such as the growth factor brain-derived neurotrophic fac-
tor (BDNF), the anti-inflammatory IL-10, the mitochon-
drial transcription (co)-factors Nrf-1 and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α) [44]. Aging is associated with Nrf2 dysfunction
and a dysregulation of this pathway has been linked to the
pathogenesis of several chronic disorders, including neu-
rodegenerative, cardiovascular, metabolic, infectious, and
pulmonary diseases as well as chronic inflammatory con-
ditions [47–49]. Accumulating evidence suggests that the
decline in the Nrf2 signaling system plays a key role in the
accumulation of pro-inflammatory mediators and oxida-
tive damage during brain aging [50, 51]. Although the
underlying mechanisms behind the impairment of Nrf2
pathway in neurodegeneration are not known, elevated
levels of oxidative stress and inflammation in patients with
neurodegenerative diseases have been reported. Studies
have established that the nuclear translocation of Nrf2 is
reduced in the hippocampus of Alzheimer’s disease (AD)
patients. Also mRNA and protein levels of Nrf2 are re-
duced in the motor cortex and spinal cord of amyotrophic
lateral sclerosis (ALS) patients [52]. It appears also from
studies with genetic deletion of Nrf2 that the absence of
Nrf2 may be detrimental during brain aging and contrib-
ute to neurodegeneration. However, there are several
promising compounds that at least in vitro are able to re-
store Nrf2 and induce neuronal protection, as discussed
below. Indeed, recent findings suggest that Nrf2 may be a
therapeutic target for the alleviation of neuroinflammation
associated with neurodegeneration [53].
The NF-κB signaling pathway in brain inflammation
NF-κB is a ubiquitous stress response pathway and one
of the well-described transcription signaling mecha-
nisms. NF-κB transcriptional activity has been associated
with neuronal plasticity and neurodegeneration [54]. In-
deed, NF-κB is a crucial signal transducer for maintain-
ing CNS homeostasis, particularly in neuronal and glial
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NF-κB coordinates the expression of numerous genes,
encoding pro-inflammatory cytokines, chemokines, and
inducible growth factors [55]. The number of target
genes of NF-κB is continuously expanding and the de-
regulation of NF-κB signaling has been detected in mul-
tiple disease states, including neurodegenerative diseases
and chronic inflammatory conditions. NF-κB orches-
trates a broad range of physiological stimuli through ca-
nonical and non-canonical pathways. In CNS, NF-κB
exists in a latent and a constitutively active form. Consti-
tutively activated NF-κB is mostly detected within the
nucleus of glutamatergic neurons and is regulated by
synaptic activity. In glia, NF-κB has a lower basal activity
and is heavily inducible [56]. Although NF-κB signalling
is tightly regulated at multiple levels, in most unstressed
cells is located in the cytoplasm in an inactive complex
consisting of two subunits of 50 kDa (p50) and 65 kDa
(p65) and an inhibitory subunit called IkB (IkBα or
IkBβ). In response to activating stimuli, IkB is phosphor-
ylated, ubiquitinated and degraded by the proteasome,
which in turn allows the nuclear translocation of NF-κB
to regulate gene expression. The most fundamental
aspects of NF-κB regulation in the brain have been ex-
tensively discussed elsewhere [57–61]. Given that a fun-
damental goal for future studies is to determine whether
activation of NF-κB is important for neuroprotection, in
the present paragraph, we would like to highlight some
data to demonstrate that NF-κB may be an activator of
neuroprotective programs. Neuroprotective effects of
NF-κB have been described in several experimental
models, indicating the potential protective value of this
essential transcription factors in the treatment of neuro-
inflammation and neurodegeneration [62]. Despite this,
the role of NF-κB in mechanisms of brain tolerance is
complex because it is involved in both protective and
damaging pathways. NF-κB supports neuronal survival
by increasing the expression of antioxidants, growth
factors, and anti-apoptotic molecules. In contrast, glial
NF-κB activation promotes neuronal death by inducing
production of pro-inflammatory cytokines [63, 64]. How-
ever, it is noteworthy to mention that NF-κB signaling
pathway has been identified as one of the major neuropro-
tective mechanism against AD [62]. The dual role of NF-
κB in neuronal death and survival is intriguing but we still
have limited knowledge on the molecular details under-
lying its actions as activator of neuroprotective programs
or inducer of neurodegenerative processes. Understanding
which determinants are implicated in switching NF-κB
from a neuroprotective to a neurotoxic activity may help
the development of new treatments for neuroinflamma-
tion. In this context, preconditioning/hormesis has been
therapeutically linked to activation of NF-κB and inhib-
ition of neuronal apoptosis [65, 66]. Therefore, a low doseof a toxic agent may trigger an adaptive stress-response
program mediated by NF-κB and provide neuroprotec-
tion. Conversely, high doses of noxious compounds can
exacerbate NF-κB activity and induce a neurotoxic re-
sponse [60, 67]. Furthermore, experimental studies have
also demonstrated that neuronal response to external
stimuli is dependent on a differential activation of NF-κB
dimers. Neurotoxic stimuli or the absence of NF-κB p50
depletes neuronal pro-survival gene products, including
anti-apoptotic proteins [68, 69]. Finally, it is remarkable to
mention that the identification of NF-κB binding sites in
the promoter region of the Nrf2 gene suggests a potential
relationship between these two transcription factors [70].
Moreover, it has been demonstrated that HO-1 induced
by the Nrf2 inhibits the NF-κB transcriptional apparatus,
and thereby HO-1 is one of the key mediator for the inter-
play between Nrf2 and NF-κB [71]. As already indicated
above, increased NF-κB activity during brain aging is asso-
ciated with enhanced production of pro-inflammatory cy-
tokines such as IL-6, TNF-α, and COX-2. Reduced Nrf2
activity is characterized by decline in HO-1, SOD, and
NQO1 leading to increased levels of oxidative stress and
neuroinflammation. A schematic illustration of the cross-
talk between Nrf2 and NF-κB in the brain is depicted in
Fig. 2.
MAPK signal transduction and its role in brain aging
Mitogen-activated protein kinases (MAPKs) belong to
the super-family of serine/threonine kinases that mediate
a wide range of cellular responses. MAPKs have emerged
as critical players that connect various extracellular signals
into intracellular response. Based on the degree of se-
quence homology, MAPK transduction cascades are orga-
nised into at least three subfamilies: the extracellular
signal regulated kinases (ERKs), the stress activated pro-
tein kinase/c-Jun N terminal kinase (JNK), and the p38
MAPK [72]. These kinases are involved in both survival
and death pathways in response to different stresses to
regulate cellular processes such as cell proliferation, sur-
vival, differentiation, and metabolism. The role of ERKs is
usually associated with pro-survival signaling, however,
depending on the type and function of a particular
neuron, activation of ERKs can either be neuroprotective
or can promote cell death [73]. For instance, in vivo
studies of neurons derived from the hippocampal tissue
revealed that BDNF regulates synapse formation and plas-
ticity by a mechanism involving ERKs, Nrf2 and forkhead
box O (FoxO) transcription factors [74]. Furthermore,
ERK activation is required for consolidation and recon-
solidation of hippocampal-dependent memory [75]. Dys-
regulation of ERK signaling has been implicated in both
neuropsychiatric and neurodegenerative disorders includ-
ing, schizophrenia, Huntington’s disease (HD), Parkinson’s
disease (PD), and AD [76–78]. JNK and p38 are well-
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Fig. 2 Schematic illustration on the role of Nrf2–NF-κB axis in bran aging. An imbalance between Nrf2 and NF-κB can lead to increased levels of
oxidative stress and neuroinflammation, resulting in structural and functional damage to nervous tissue
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vated by stress signals such as UV light, inflammatory cy-
tokines, and DNA damaging agents. In particular, a large
body of evidence indicates that JNK is a key regulator of
apoptotic and inflammatory pathways which are activated
during neuro-inflammaging, PD, HD, and AD. Indeed,
JNK is involved in inflammatory responses in astrocytes
and in primary glial cells. JNK is activated by TNF, IL-1,
UV light, and heat shock. Moreover, JNK activation in the
brain is associated with intracellular Aβ accumulation and
neuronal death in AD patients. It has been also reported
that JNKs activity is involved in the regulation of neuronal
survival via the maintenance of mitochondrial homeosta-
sis [79–81]. Finally, evolving evidence suggests that p38
plays specific roles in inflammation, cell death, and senes-
cence. Disruption of p38 signaling in neural cells contrib-
utes to the pathogenesis of many neurodegenerative
diseases including AD, HD, and PD [82]. p38 has been
shown to be essential for the maintenance of dopamin-
ergic neurons and oxidative stress and p38 signalling
cascade regulate pro and anti-apoptotic phenotypes of
dopaminergic neurons [83]. Several studies have investi-
gated the function of p38 in the context of neuroin-
flammation. Astrocytic p38 signalling is activated by
inflammatory cytokines such as IL-1β and TNF-α. It has
also been found that p38 in AD is one of the main kinases
responsible for excessive tau phosphorylation.
Moreover, accumulation of Aβ plaques is partially me-
diated through misregulated activity of p38 cascade [84].
Inhibitors of p38 confirm that an elevated activation of
this pathway is a critical contributor to neuronal damage
and neuroinflammation [85].
Sirtuin-FoxO longevity pathway
Sirtuins (SIRTs) are members of the class III histone
deacetylases, and so far seven sirtuin genes (sirtuins 1–
7) have been characterized in mammals [86]. A largenumber of studies have shown that SIRT1 can alter the
fate of a neuron promoting cell survival against stress.
SIRT1 appears to be a crucial component for neuronal
plasticity and cognitive functions because it is also in-
volved in dendritic and axonal growth. In the brain,
SIRT1 regulates numerous neuroprotective functions,
including antioxidant and anti-inflammatory response,
antiapoptosis, and mitochondrial biogenesis [87, 88]. An
emerging target of the sirtuins is the family of FoxO
transcription factors [89]. The mammalian FoxOs are
composed of four members: FoxO1, FoxO3, FoxO4, and
FoxO6. Temporal and tissue specific differences in ex-
pression can be observed with FoxO1 and FoxO3 almost
ubiquitously expressed, FoxO4 highly expressed in kid-
ney, colorectal and muscle tissue and FoxO6 mainly
expressed in the liver and brain. FoxOs are involved in a
myriad of cellular processes and programs including en-
ergy metabolism, cell cycle regulation, apoptosis, au-
tophagy, immunity, inflammation, resistance to oxidative
stress, stem cell maintenance and appear to play a con-
served “prolongevity” role observed in worms through to
human beings [90]. FoxOs also modulate key aspects of
stress response and survival pathways in neurons [91].
Therefore, FoxOs have dual roles in survival and cell
death and gene-specific contexts determine the effects of
FoxOs on gene expression. Although the effects of SIRT1
on the FoxO target genes are complex, FoxOs can
recognize and bind to different sites within the SIRT1 pro-
moter region to induce transcription. SIRT1 activates
several members of the FoxO family. Notably, SIRT1 posi-
tively controls FoxO transcription by shifting FoxO-
dependent response away from cell death and toward
stress resistance, particularly in the case of oxidative stress
[92]. Three FoxO isoforms are commonly expressed in the
brain. FoxO1 is strongly expressed in neuronal subsets of
the hippocampus, whereas FoxO6 is highly enriched and
expressed throughout the entire adult hippocampus, and
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onal connectivity [93]. Of the isoforms, FoxO3 is the most
diffusely expressed in the brain and has been shown to be
strongly associated with human longevity including a re-
duced risk for cognitive decline with age for those who
possess the protective “G” allele. [94]. SIRT1 deacetylates
FoxO3, reducing FoxO-mediated apoptosis but potenti-
ates FoxO-induced cell cycle arrest [95]. SIRT1 and
FoxO3 form a complex in response to oxidative stress,
and the sites of FoxO3 that appear to be deacetylated by
SIRT1 are K242, K245, and K262 [96, 97]. Therefore, the
effect of acetylation on FoxO3 has a dual role on function
because SIRT1 can increase the ability of FoxO3 to induce
cell cycle arrest and resistance to oxidative stress but can
also inhibit FoxO3 to induce cell death [89, 98]. Further-
more, the SIRT1-FoxO3 network is associated with the
induction of DNA repair proteins. In the context of be-
havioural adaptations to cocaine, new findings have dem-
onstrated that the induction of SIRT1 deacetylates and
activates FoxO3, which then induces many gene targets
involved in DNA repair in the brain [99]. Another SIRT
widely expressed in neurons and astrocytes is SIRT3. It
has been shown to have a major involvement in ROS
regulation, deacetylating FoxO3 with consequent expres-
sion of CAT and mnSOD [100, 101]. Recently, Rangarajan
et al. reported for the first time that SIRT3 expression
is induced in activated microglia in vivo and activates
antioxidant genes through nuclear translocation of
FoxO3 [102].FoxONucleus
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Fig. 3 The main intracellular targets involved in the neuroprotective effects o
activity seem to converge in the modulation of stress response pathways. For
expression of phase II detoxifier genes. The kinases p38, ERK and JNK are also
pathways in response to different stresses. Activation of SIRT1 can regulate Fo
response proteins. FoxO is also regulated by ERK in response to a variety of st
the activation of Nrf2. Phytochemicals and/or activated SIRT1can also inhibit NNeuroprotective activity of phytochemicals
against neuro-inflammaging
Dietary phytochemicals may have a profound effect on
many aspects of neuro-inflammaging. Several studies
have revealed that the neuroprotective activities of phy-
tochemicals typically occur in dose- and time-dependent
manner [42, 103]. A variety of mechanisms appear to
underlie the neuroprotective action of phytochemicals.
Although research has focused predominantly on anti-
oxidant properties of dietary phytochemicals, the ability
of these compounds not only has the potency to scav-
enge free radical effects in the brain but it has also
demonstrated that specific phytochemicals target key
stress-activated signaling pathways involved in neuro-
protection (Fig. 3). Substantial in vitro and in vivo evi-
dence have suggested that many phytochemicals can
affect the expression of numerous genes encoding pro-
survival proteins, including antioxidant enzymes, neuro-
trophic or anti-apoptotic factors. In the next sections,
we will present the main classes of food phytochemicals
and their emerging role as hormetic inducers of neuro-
protective pathways relevant for brain aging.
Curcumin
Curcuma species, particularly C. longa (turmeric) have
been used in Southeast Asian countries for thousands of
years as a food preservative and for medical conditions.
Among curcuminoids, the main components in Cur-
cuma species, curcumin is the most studied and shows aCell Membrane
 Response Pathways
RT1
ROS
IL-
TNF-
COX-2
IO&NS
NRF2 NF-kB
HO-1
NQO1
SOD
f phytochemicals. Most of the phytochemicals with neuroprotective
example, phytochemicals can interact directly with Nrf2, allowing the
modulated by phytochemicals, regulating both survival and death
xO, which modulate genes that encode antioxidant and other stress-
imuli, including IO&NS and phytochemicals. ERK activation often leads to
F-κB, reducing the expression of inflammatory mediators
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muomodulatory activity is well-documented and in vivo
(100 mg/kg) and in vitro (10 μM) studies have also dem-
onstrated that curcumin can protect dopaminergic neu-
rons against microglia-mediated neurotoxicity and reduce
brain inflammation in a concentration-dependent manner
[105–108]. Recent studies also indicate an epigenetic
role of curcumin, which inhibits the expression of pro-
inflammatory mediators by affecting histone acetylation of
transcription factors and methylation pattern of gene pro-
moters associated with inflammatory response [109]. Cur-
cumin treatment (2–8 μM) inhibits in a dose-dependent
manner the activation of microglial cells by diminishing
the production of NO and reducing the secretion of IL-
1β, IL-6 and TNF-α (5–20 μM) [110, 111]. Moreover, cur-
cumin blocks the LPS-mediated induction of COX2 via
inhibition of NF-κB, activator protein 1 (AP1) (2–16 μM),
and signal transducers and activators of transcription
(STATs) (5 or 10 μM) [112, 113]. DNA-microarray ana-
lyses revealed that 20 μM of curcumin has a strong impact
on the microglial transcriptome, leading to an anti-
inflammatory and neuroprotective phenotype in LPS-
triggered microglia [114]. These concentrations may be
indicative of clinical efficacy, since curcumin preparations
with enhanced bioavailability (delivered orally) can cross
the blood–brain barrier and reach therapeutic concentra-
tions up to 3 μM [115, 116]. Moreover, it should be men-
tioned that peak plasma concentrations (approximately
1.6 μM) in mice were achieved 15 min after the intraperi-
toneal administration of 100 mg/kg curcumin, followed by
brain accumulation within one hour [117]. In an experi-
mental animal model of chronic epilepsy, 60–100 mg of
daily curcumin are effective in attenuating glial immuno-
reactivity with ameliorative effects on cognitive deficits
[118]. Curcumin administration (100 mg/kg) to rats under
hypoxic conditions attenuated the upregulation of NF-κB,
thereby leading to concomitant downregulation of pro-
inflammatory cytokine levels (IL-1, IL-2, IL-18 and TNF-
α) and cell adhesion molecules (P-selectin and E-selectin)
[119]. Also, repeated intrathecal injection of curcumin
(50, 100, 200 mg/kg) dose-dependently attenuates glial ac-
tivation and spinal neuroinflammation in a rat model of
monoarthritis [120]. The TLR4 complex is an important
mediator of neuroinflammatory events and treatment
with curcumin (50, 100, 200 mg/kg) attenuated TLR4-
mediated acute activation of microglia/macrophages, pro-
inflammatory mediator release and neuronal apoptosis in
the injured brain tissue of rats via inhibition of the
MyD88/NF-κB signaling cascade [121]. As reviewed else-
where, curcumin is also a Nrf2 inducer that upregulates
antioxidant defence mechanisms [15]. Recent cell and
animal studies have shown that the neuroprotective effects
of curcumin (approximately at concentrations of 5 to
25 μM) involves the Akt/Nrf2 pathway, which is consistentwith the fact that Nrf2 participates in the neuroprotective
effects of curcumin against oxidative damage [122, 123].
Pretreatment with curcumin (5–30 μM) induces neuro-
protective antioxidant effects against hemin-induced neur-
onal death, regulating the expression of Nrf2, HO-1 and
glutathione synthesis [124]. Axon degeneration is medi-
ated by microglial MyD88/p38 MAPK signalling and JNK
phosphorylation. A new quantitative approach for moni-
toring axon degeneration found that curcumin (10 μM)
protects axons from degeneration during neuroinflamma-
tion, inhibiting axonal JNK phosphorylation [125]. The
neuroprotective action of curcumin also involves the
modulation of SIRT1. Recent observations indicate that
SIRT1 signaling activation is associated with the neuropro-
tective effect of curcumin and preatreatment of curcumin
(50 mg/kg) attenuated inflammation, apoptosis, and mito-
chondrial dysfunction in a rat model of ischemic brain
[126]. Curcumin (5–10 μM) was also effective in inducing
FoxO3a activity in monocytes/macrophages, suggesting a
potential protective mechanism against oxidative damage
in the inflammatory cells of the vascular system [127].
Anthocyanins
Anthocyanins are a class of flavonoids consisting of water-
soluble colored pigments. Berry fruits with red, blue or
purple colors constitute one of the most important
sources of dietary anthocyanins [128]. These compounds
are consumed as part of a normal diet and in the United
States the human intake of anthocyanins has been ap-
proximately estimated to be 180–255 mg/day. Anthocya-
nins after ingestion reach the circulatory system within
0.25–2 h [129]. Several studies have indicated that antho-
cyanins from berries may enhance cognitive and motor
function during aging due primarily to their antioxidant
and neuroprotective properties [130, 131]. Although only
a few studies have explored the specific actions of antho-
cyanins in the context of neuroinflammation, it was re-
cently reported in an experimental model of multiple
sclerosis (MS) that anthocyanins (100 mg/kg) suppress the
secretion of pro-inflammatory mediators and protect cel-
lular components against oxidative damages induced by
demyelination [132]. Moreover, in high-fat-fed animals
chronic intake of an anthocyanin extract from blackberry
(25 mg/kg) may be capable of preventing the detrimental
effects of neuroinflammation with positive effects on
synaptogenesis and synaptic plasticity [133]. Anthocy-
anins protect neuronal cells from pro-oxidant and pro-
inflammatory damage via diverse mechanisms, including
modulation of Nrf2 and inhibition of NF-κB pathways
[134]. For instance, an anthocyanin-rich açaí extract
(1 μg/mL) attenuated oxidative stress in rat primary astro-
cyte cultures through modulation of Nrf2 pathway,
thereby restoring the GSH/GSSG ratio and protecting the
astrocytic membranes from lipid peroxidation [135].
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are efficient inducers of Nrf2 activation and can be consid-
ered a good treatment option for inflammation-mediated
disorders such as atherosclerosis [136]. Anthocyanins
from blueberry, blackberry, and blackcurrant exhibited a
similar degree of anti-inflammatory effects and these
compounds suppressed the expression and secretion of
pro-inflammatory mediators in macrophages by inhibiting
nuclear translocation of NF-κB [137]. In another study,
the neuroprotective effects of anthocyanins have also been
reported in the hippocampus of postnatal rat brain. An-
thocyanins (100 mg/kg) inhibited the ethanol-activated ex-
pression of JNK, NF-κB, COX-2, as well as attenuated
neuronal apoptosis [138]. A blueberry anthocyanin frac-
tion significantly inhibited the LPS-induced production of
pro-inflammatory mediators NO, iNOS and COX2 in BV2
microglial cell and this effect was due to the attenuation of
NF-κB nuclear translocation [139]. Berries also contain
high levels of proanthocyanidins that have neuroprotective
effects similar to those of anthocyanins. Findings in pri-
mary hippocampal neuronal cells treated with various
blueberry fractions (anthocyanins 15 μg/mL; proanthocya-
nidins 14 μg/ml) and exposed to Aβ42 and LPS showed
that the major neuroprotective effects of blubbery involve
reduction of NF-κB, p38, and JNK [140]. Also bilberry and
lingonberry contain high amounts of anthocyanins and
proanthocyanidins. At final concentrations of 1–10 μM
these molecules exert protective effects against blue light-
emitting diode (LED) light-induced retinal photoreceptor
cell damage by regulating the activation of NF-κB, p38
MAPK, autophagy and pro-apoptotic proteins [141]. In
senescence-accelerated mice prone 8 (SAMP8) mice, blue-
berry extracts (200 mg/kg) and cyanidin-3-O-galactoside
(Cy-3-GAL) (50 mg/kg) may reverse the declines of cogni-
tive and behavioural function, increasing SOD activity, re-
ducing MDA levels in brain tissues and promoting
hippocampal ERK expression [142]. Red wine contains a
broad spectrum of anthocyanins (Delphinidin-3-glucoside
1.6 mg/L; Petunidin-3-glucoside 2.8 mg/L; Peonidin-3-
glucoside 3.8 mg/L; Malvidin-3-glucoside 28.9 mg/L) and
a recent study supports the notion that the enhanced mye-
lination after wine treatment in an in vitro mouse model
of peripheral nerve system may be induced by SIRTs acti-
vation, particularly SIRT1 [143]. Although there are no
studies demonstrating that anthocyanins affect the activity
of members of the FoxO class of transcription factors, ex-
posure of Caenorhabditis elegans to anthocyanin-rich
purple wheat (100 μg/mL) leads to a translocation of DAF-
16/FoxO to the nucleus, where it stimulates the expression
of stress resistance and longevity-related genes [144].
Flavanols: catechin and epicatechin
Flavanols (also referred to as flavan-3-ols) are one of the
largest subclass of flavonoids consisting of monomers,oligomers, and polymers. Catechin and epicatechin are
examples of monomeric flavanols and these compounds
were found in higher concentrations in cocoa than in
other plant-based foods. Flavanol concentrations found
in cocoa products are dependent on the cocoa cultivar
type, post-harvest handling practices, and manufacturer
processing techniques [145]. Fresh and fermented cocoa
beans contain approximately 10 % flavanols (100 mg/g)
prior to processing, while the cocoa powder consumed
by the Kuna Indians contains about 3.6 % flavanols
[146]. Although little is known about the pharmacoki-
netic profiles of flavanols in the brain, catechin and epi-
catechinin can cross the blood–brain barrier to exert
their neuroprotective effects [147]. The process is time‐
dependent and epicatechin was found to reach a peak
2–3 h after ingestion and return to baseline value by 6–
8 h after consumption of flavanol‐rich chocolate [148].
Thus, it seems plausible that flavanols may beneficially
influence the brain, promoting neuroprotection and
healthy brain aging. The neuroprotective effects of flava-
nols are believed to occur through the modulation of
several pathways. First, epicatechin can specifically inter-
act with Nrf2-mediated antioxidant response. The ad-
ministration of epicatechin (30 mg/kg) dose-dependently
protects transient ischemia-induced brain injury in both
pre- and post-treatment animal studies by activating the
Nrf2/HO1 pathway [149]. In addition, it was recently
demonstrated in mice that epicatechin (15 mg/kg) pro-
tects the brain against injury after traumatic brain injury
via Nrf2-dependent and -independent pathways, im-
proving neurologic function, cognitive performance and
depression-like behaviours [150]. Pretreatment with 50
or 100 μM of epicatechin also protected primary neu-
rons from oxygen glucose deprivation by increasing
neuronal viability and reducing protein oxidation. This
effects occurred concomitantly with increased Nrf2-
responsive antioxidant protein expression. In the same
study, the neuroprotective effect elicited by epicathechin
(15 mg/kg) in an animal model of focal brain ischemia
was associated with reduced microglia/macrophage acti-
vation/recruitment [151]. Further data indicate that cat-
echin exhibits anti-inflammatory effects in LPS-induced
BV-2 microglial cells by suppressing the production of
pro-inflammatory mediators and attenuating NF-κB acti-
vation through regulation of ERK and p38 MAPK
pathways [152]. The protective effects of catechin were
also demonstrated in experimental models of AD where
inflammatory mediators like TNF-α, IL-1β levels and
expression of iNOS were significantly attenuated by
catechin pretreatment (20 mg/kg) [153]. A recent study
revealed that oral administration of cocoa extract (22.9 mg/
kg) protects the diabetic retina from glial reaction through
SIRT1 activity, providing further evidence that epicatechin
can cross the blood retinal barrier and be found in the
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of animals treated with cocoa [154].
Oleuropein and hydroxytyrosol
Virgin olive oil (VOO) and extra-virgin olive oil (EVOO)
are extracted from olive fruits of Olea europea and their
health beneficial effects are well established. An exten-
sive literature has demonstrated that these effects can be
attributed to many different substances belonging to the
phenolic fraction of VOO and EVOO. However, the con-
centration of these compounds in VOO and EVOO is
strongly affected by the particular olive cultivar, by agro-
nomic and environmental factors, and by the extraction
and storage conditions [155]. In particular, oleuropein
and hydroxytyrosol are the most investigated bioactive
phytochemicals and may open new avenues for the de-
velopment of neuroprotective and/or neurorestorative
strategies [156, 157]. Oleuropein and hydroxytyrosol have
shown neuroprotective activity by acting against oxidation
and inflammation and interfering with amyloid Aβ and
tau protein aggregation. Indeed, St-Laurent-Thibault et al.
found that these compounds (100 μg/mL) can reduce Aβ-
induced toxicity in cultured neuroblastoma cells through
involvement of NF-κB signaling [158]. Furthermore, it was
recently demonstrated that hydroxytyrosol and oleuropein
may be effective as tau aggregation inhibitors at low con-
centrations (10 μM) in vitro [159]. Mechanistic studies in
human neuroblastoma cells reveal that an effective con-
centration of 5 μM hydroxytyrosol can protect against
methylmercury (MeHg)-induced neurotoxicity, causing
upregulation of pro-survival proteins including Nrf2 [160].
More interestingly, hydroxytyrosol given to rats at doses
of 10 and 50 mg/kg/day improves neurogenesis and cogni-
tive function in prenatally stressed offspring. In this study,
hydroxytyrosol supplementation increased transcription
factors FoxO1 and FoxO3, as well as phase II enzyme-
related proteins, including Nrf2 and HO-1, which may
contribute to the decreased oxidative stress and increased
mitochondrial function [161]. The neuroprotective effect
of hydroxytyrosol was investigated in a model of hypoxia-
reoxygenation in rat brain slices after in vitro incubation
of this compound or after 7 days of oral treatment with 5
or 10 mg/kg per day. Hydroxytyrosol significantly inhib-
ited the efflux of lactate dehydrogenase (LDH), a marker
of brain cell death. Other well-known antioxidants such as
vitamin E and N-acetyl-cysteine had no neuroprotective
effect in this experimental model [162]. Further observa-
tions demonstrate that 100 μM of phenolic compounds
(tyrosol, hydroxytyrosol, and oleuropein) from olive oil
can inhibit the effect of the chronic inflammatory micro-
environment on glioblastoma through regulation of TNF-
α, COX-2, JNK, ERK and NF-κB [163]. Hydroxytyrosol
also improves neuronal survival, mitochondrial function
and reduces oxidative stress in the brain cortex of db/dbmice. After 8 weeks of hydroxytyrosol administration
at doses of 10 and 50 mg/kg, this compound induced
phase II antioxidant systems regulated by Nrf2, acti-
vated SIRT1 and the energy-sensing protein network
known to regulate mitochondrial function and oxida-
tive stress responses [164].
Human studies
The link between diet and health is extremely complex
and the efficacy of phytochemicals to improve aspects of
human brain function during aging is somewhat equivo-
cal. However, over the past decade one of the preventa-
tive strategies that has been increasingly accepted is
promoting the brain’s endogenous defenses through
supplementation with phytochemical-rich foods. The
molecular bases for the use of phytochemicals as nutra-
ceutical intervention to prevent cognitive decline are of
crucial importance. Animal and in vitro studies have
contributed significantly to our understanding, showing
a dose-dependent neuroprotective effects. Despite diffi-
culties associated with absorption, bioavailability, and
biomarkers, as well as length of the trial and realistic
doses, encouraging signs are emerging from intervention
and observational studies with improved formulations
and appropriate cohorts [165, 166]. Moreover, in order
to assess the cause-effect relationship between the con-
sumption of phytochemicals and the beneficial outcome
on neuroinflammatory responses, an appropriate study
design should always take into account the challenging
and controversial regulatory framework of the corre-
sponding authorities worldwide (FDA in USA; EFSA in
Europe; FOSHU-Ministry of Health Labour and Welfare
in Japan, etc.). In designing human intervention studies
and provide high-quality evidence for brain health bene-
fits of phytochemicals, the following factors need to be
considered: 1) the phytochemical needs to be sufficiently
characterised, 2) optimal physiologic dose, 3) character-
istics of targeted populations including their nutritional
status, health condition, and genetic background, 4) se-
lection of clinically relevant, sensitive, reproducible, and
feasible endpoints, and 5) length of the intervention
[167–170]. Moreover, it should be always considered
that a phytochemical functional food has a beneficial ef-
fect on the health status, thus, the study population
should be composed of healthy subjects. However, to
date, several human studies have investigated the cogni-
tive enhancing effects of phytochemicals in subjects with
both normal cognitive function and people with mild
cognitive impairment. The neuroprotective actions of
phytochemicals on cognitive function have been attrib-
uted to a number of different mechanisms, including
antioxidant and anti-inflammatory activities, and in-
creased neurogenesis in the areas of the brain associated
with cognition [42]. The lack of specific health claims
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ably due to the fact that a cluster of clinically relevant
markers that reflect the neuroinflammatory state is not
well-established. The intake levels and the optimal tim-
ing of consumption to prevent age-related cognitive de-
cline in humans have yet to be determined. Despite this,
completed human studies on phytochemicals mentioned
here are discussed below. The efficacy of curcumin in
patients with cognitive decline has been debated, how-
ever, Ringman et al. conducted the first 24-week, rando-
mised, double-blind, placebo-controlled study measuring
cerebrospinal fluid (CSF) biomarkers and evaluating the
efficacy of two dosages of curcumin (2 g/d or 4 g/d) in
36 subjects with mild-to-moderate AD. Bioavailability
was reported as a limitation and the results showed no
significant differences in cognitive function, in CSF Aβ
or tau, between placebo and intervention groups [171].
DiSilvestro et al. evaluated the health promoting effect
of curcumin under normal physiological conditions in
healthy middle-aged subjects (n 38, 40–60 years). In this
placebo-controlled study 80 mg of curcumin (400 mg of
Longvida-optimised curcumin) was given orally for
4 weeks, investigating several blood and saliva bio-
markers associated with lipids, inflammation, immunity
and stress, as well as Aβ levels. Cognitive measures were
not included in the study design. Significant changes
were shown for several of these markers including in-
creased catalase, NO and antioxidant status, with low-
ered plasma alanine amino transferase and Aβ levels
[172]. Cox et al. randomised 60 healthy adults aged 60–
85 using the same curcumin formulation and doses used
by DiSilvestro. The authors investigated acute (1 h post
dose) and chronic (1-month duration) effects of curcu-
min intake on mood, blood, and cognition biomarkers.
Attention and working memory tasks were improved
one hour after administration of curcumin but also after
chronic treatment [173]. Age-related cognitive decline is
often accompanied by depression. A recent exploratory
study provided a partial support of the efficacy of cur-
cumin (500 mg, twice daily) given to 50 participants di-
agnosed with major depressive disorder. This study
demonstrated that curcumin supplementation influences
several peripheral biomarkers from salivary, urinary and
blood samples and may be associated with its anti-
depressant mechanisms of action [174].
There is also mounting evidence that dietary supple-
mentation with anthocyanins improve aspects of mem-
ory and cognition in older adults. First, supplementation
with anthocyanins (300 mg/d) to healthy adults (n 120,
40–74 years) for 3 weeks decreased the plasma concen-
trations of several NF-κB-regulated pro-inflammatory
mediators [175]. Furthermore, a dietary intervention with
an anthocyanin-maqui berry extract (486 mg/d) improve
oxidative status (Oxidised LDL and F2-isoprostanes) inhealthy, overweight, and smoker subjects (n 42 partici-
pants, 45–65 years) after 4 weeks of supplementation
[176]. Daily consumption of blueberry juice for 12 weeks
containing anthocyanins at 877 mg/L improved memory
function in older adults with early memory decline (n 9,
mean age 76.2) [177]. Anthocyanins comprise 46 % of de-
tected polyphenols in samples of Concord grape juice.
Subjects (n 21, mean age 76 years) who received this grape
juice for 16 weeks showed increased neural activation in
cortical regions along with improved memory function
[178]. A recent randomised clinical trial was conducted to
assess changes in cognitive function of older adults (n 49,
+70 years) with mild-to-moderate dementia after daily
consumption of an anthocyanin-rich juice (200 ml/d) over
12 weeks. Secondary outcomes included also blood anti-
inflammatory markers (CRP and IL-6). Improvements in
verbal fluency, short-term memory and long-term mem-
ory were found in the intervention arm but markers of in-
flammation were not altered [179].
The neurobiological impact of flavanols occurs in two
major ways: 1) enhancement of cerebral blood flow
throughout the central and peripheral nervous system;
2) interactions with brain signaling cascades increasing
expression of neuroprotective and neuromodulatory pro-
teins [180]. To date, evidence for antioxidative and anti-
inflammatory properties of flavanols on cognitive decline
in human aging is rather limited. However, the known
benefits on cerebral blood flow may represent a promis-
ing approach in treating cerebrovascular disorders in the
elderly. The first dietary intervention study to demon-
strate the efficacy of consumption of flavanols on cogni-
tive function was conducted by Desideri et al. in 90
elderly individuals with mild cognitive impairment
(mean age, 71 years). In this study, formally known as
Cocoa, Cognition, and Aging (CoCoA) study, the sub-
jects were randomised to consume once daily for 8 weeks
a drink containing 990 mg (high flavanols), 520 mg
(intermediate flavanols), or 45 mg (low flavanols) of
cocoa flavanols. The improvement of cognitive perform-
ance was recorded in the high- and moderate-flavanol
groups, suggesting also a possible role of glucose metab-
olism in modulating cognitive function [181]. More re-
cently, a parallel-arm of CoCoA study involved 90
elderly individuals without clinical evidence of cognitive
dysfunction who were randomly assigned to consume
daily for 8 weeks a drink containing 993 mg (high flava-
nol), 520 mg (intermediate flavanol), or 48 mg (low
flavanol) of cocoa flavanols. The results of this study in-
dicate that the regular intake of cocoa flavanols can im-
prove aspects of cognitive performance and these effects
appear to be dependent on the amount of flavanols in-
take [182]. Furthermore, the dentate gyrus (DG) is a key
factor in age-related cognitive decline and 3 months of
high cocoa flavanol (900-mg daily dose) consumption in
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the aging human hippocampal circuit [183]. Finally, high
cocoa flavanol drink (494 mg total flavanols; epicatechin
89 mg) improves regional cerebral perfusion in 18 healthy
older adults (mean age 61 years), providing additional evi-
dence that cocoa flavanols are associated with benefits for
cognitive performance [184]. All these results support the
crucial role of flavanols as human dietary supplements in
slowing down cognitive decline during brain aging.
Several health claims for olive oil and its derivatives
have been assessed in recent years. The only authorized
health claim in Europe, relates the impact of olive phen-
olic compounds on the protection of blood lipids from
oxidative stress. “A daily intake of 20 g of olive oil, which
contains at least 5 mg of hydroxytyrosol and its deriva-
tives (e.g. oleuropein and tyrosol) provides the expected
beneficial effects” [185]. Although the direct cognitive
benefits of olive oil require further confirmation and
clinical evidence is still lacking, neuropsychological tests
in a PREDIMED subcohort of cognitively healthy indi-
viduals (n 447, mean age, 66.9 years) demonstrated that
adherence to the Mediterranean diet supplemented with
EVOO (1 L/week) or nuts (30 g/d) was associated with
improved cognitive functions at 4-year follow-up. The
authors also measured urinary hydroxytyrosol reporting
that the Mediterranean diet plus EVOO group had in-
creased levels of hydroxytyrosol (49.6 μg/L), indicating
good adherence with the supplemental foods [186].
However, Crespo et al. recently reported in a double-
blind, randomized, placebo-controlled 1-week study that
two hydroxytyrosol doses (5 and 25 mg/d) did not mod-
ify Phase II enzyme expression in peripheral blood
mononuclear cells (PBMCs) of 22 young healthy volun-
teers [187]. Another study investigated plasma hydroxy-
tyrosol concentration in 62 healthy elderly subjects aged
65–96 years, showing a significant increase after a 6-
week daily intake of polyphenol-rich EVOO with high
oleuropein contents. The results also show a significant
increase of CAT in erythrocytes and a decrease of SOD
and glutathione peroxidase activity after EVOO intake
[188]. Although several other human studies are still un-
derway, few clinical trials have been conducted thus far.
Therefore, it is not possible to make any conclusions
concerning the clinical significance of phytochemicals in
counteracting neuroinflammation associated with aging
and their potential in enhancing cognition. Importantly,
even though the concept of hormesis has been explored
extensively in terms of its applicability in aging, solid hu-
man confirmations are required by future trials.
Conclusions
Current nutrition recommendations are also directed to
prevent neurodegenerative pathologies. Recent evidence
suggests that dietary phytochemicals may be particularlyattractive for preventing dementia and geriatric cognitive
disorders. Brain aging predisposes to neurodegeneration
via several mechanisms that in part converge on dysreg-
ulation of redox-state and inflammatory pathways. From
the topics discussed above, light and shade rise on the
effects of phytochemicals on human brain health. How-
ever, even though experimental findings have not always
translated to a definitive clinical effect, the antioxidant
and anti-inflammatory properties of phytochemicals have
been widely accepted. Despite the abundance of the litera-
ture in this field, a clearer understanding of the mecha-
nisms of action of phytochemicals as modulators of cell
signalling pathways involved in neuro-inflammaging play
a pivotal role for the evaluation of these molecules in
short-term or long-term nutritional intervention trials.
Furthermore, the preventive effects of phytochemicals on
the onset of neurodegenerative conditions still needs to be
critically explored. Many dietary supplements containing
phytochemicals are already commercially available and
marketed to prevent or ameliorate specific diseases, in-
cluding age-related cognitive decline. The majority of
these products are not substantiated by solid scientific evi-
dence and have not yet been approved by the EFSA and/
or FDA. For instance, it is unclear the concentrations of
phytochemicals that enter the bloodstream and cross the
blood-brain barrier. Although delivery systems, such as
nanoparticles, might represent a successful strategy for
drug delivery into CNS, the bioavailability continues to be
highlighted as a major concern in human intervention
studies. The quality of the compounds is another major
source of variability and conflicting results. A further chal-
lenge is to understand whether dietary phytochemicals
have appropriate effects on specific epigenetic mecha-
nisms in specific genes or sets of genes. Brain aging is in-
deed associated with substantial changes in epigenetic
profiles and several preclinical studies have revealed that
bioactive phytochemicals play an important role in the
modulation of overall epigenetic modifications (histone
modifications, DNA methylations and microRNA). An-
other limitation to the clinical application of these
compounds is the lack of knowledge on questions
concerning the complex metabolic fate of dietary phy-
tochemicals, the role of the gut microbiota in the
bioconversion of phytochemicals, and whether the bac-
terial transformations produce metabolites with in-
creased biological activity. Future studies addressing
these issues are needed. Observational studies and diet-
ary intervention trials in large cohorts of healthy
subjects are essential to evaluate whether these phyto-
chemicals can help to prevent age-related neurodegener-
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